貝瑞基因(000710.SZ)2019年度淨利潤升45.7%至3.91億元
格隆匯4月15日丨貝瑞基因(000710.SZ)發佈2019年年度報告,實現營業收入16.18億元,同比增長12.35%;歸屬於上市公司股東的淨利潤3.91億元,同比增長45.70%;歸屬於上市公司股東的扣除非經常性損益的淨利潤2.94億元,同比增長15.87%;基本每股收益1.10元。
期內,基礎科研服務實現收入3.61億元,同比增長174.54%,產品模式服務收入5.83億元,同比增長22.31%,為公司主要利潤增長推動因素。
公司主營業務為以高通量測序技術為基礎的基因檢測和設備、試劑銷售。
作為基因測序領域具有影響力的企業,公司致力於實現基因測序技術向臨牀應用的全面轉化,通過服務模式和產品模式為各級醫院、第三方醫學實驗室等醫療機構提供醫學產品及服務,範圍覆蓋生育健康領域、遺傳病檢測、腫瘤基因檢測及腫瘤早診早篩等全生命週期臨牀需求。
同時,公司專注於用測序技術促進生命科學的研究,為科研院校、研究所等科研機構提供基於高通量測序的基礎科研服務。基於客户的不同需求,公司為客户提供實驗室整體解決方案,並銷售測序所需的試劑及儀器。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.